Alfred Hulse, DO
Family Medicine · Fort Worth, TXNPI 1225063019
Payments from drug & device makers
Across 528 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- AbbVie$1K
- Lilly USA, LLC$716
- Sanofi-aventis U.S. LLC$642
- Bayer$456
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,65399%
- Education$771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 118 | $1,766 |
| AstraZeneca | 70 | $1,391 |
| AbbVie(2 entities) | 64 | $1,030 |
| Lilly USA, LLC | 42 | $716 |
| Sanofi-aventis U.S. LLC | 39 | $642 |
| Bayer | 17 | $456 |
| Amarin Pharma, Inc. | 37 | $376 |
| Boehringer Ingelheim | 21 | $347 |
| Pfizer | 23 | $319 |
| GSK | 15 | $274 |
| Amgen | 10 | $183 |
| Astellas Pharma US Inc | 11 | $161 |
| Abbott | 7 | $132 |
| Merck | 8 | $117 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $97 |
| Dexcom, Inc. | 5 | $91 |
| Medtronic | 3 | $57 |
| Eisai Inc. | 3 | $52 |
| Novartis | 3 | $51 |
| Exact Sciences | 3 | $46 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Sanofi Pasteur Inc. | 3 | $42 |
| Inspire Medical Systems, Inc. | 2 | $41 |
| Johnson & Johnson | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $34 |
| Olympus America Inc. | 1 | $28 |
| Genentech USA, Inc. | 2 | $25 |
| Lundbeck LLC | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Seqirus USA Inc | 1 | $22 |
| Shield Therapeutics Inc | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Nevro Corp. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Si-bone, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,730 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 125 | $143,521 |
| EliquisApixaban | 94 | $79,495 |
| MounjaroTirzepatide | 45 | $53,421 |
| JardianceEmpagliflozin | 50 | $45,238 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 32 | $28,874 |
| JanuviaSitagliptin Phosphate | 15 | $19,155 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $14,000 |
| MyrbetriqMirabegron | 17 | $11,915 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,720 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $5,487 |
| Rosuvastatin Calcium | 384 | $4,478 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,395 |
| Pregabalin | 20 | $3,224 |
| Valsartan | 141 | $2,736 |
| Metoprolol Succinate | 138 | $2,724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,766 | $143,521125 claims |
| PfizerEliquis | $319 | $79,49594 claims |
| Lilly USA, LLCMounjaro | $716 | $53,42145 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $347 | $50,95862 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $642 | $28,87432 claims |
| MerckJanuvia | $117 | $19,15515 claims |
| AstraZenecaBreztri Aerosphere | $1,391 | $14,00014 claims |
| Astellas Pharma US IncMyrbetriq | $161 | $11,91517 claims |
| AbbVieArmour Thyroid, Synthroid | $1,030 | $2,28030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Fort Worth
- William SegerFort Worth$27.5M
- Mark KochFort Worth$7.6M
- Isaac WatembergFort Worth$3.2M
- James HarveyFort Worth$2.7M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.